KCM
SUPN icon

Kennedy Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Kennedy Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-669,954
Closed -$8.1M – 749
2015
Q1 		$8.1M Buy
669,954
+539,985
+415% +$5.1M 0.14% 259
2014
Q4 		$1.08M Buy
+129,969
New +$1.09M 0.02% 651

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Kennedy Capital Management's SUPN Position: Q2 2015 in Review

Kennedy Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 669,954 shares — an estimated $8.1M sold.

Kennedy Capital Management first reported a position in SUPN in Q4 2014 and held it in 2 quarters. The position peaked at $8.1M in Q1 2015. 165 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • Kennedy Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Kennedy Capital Management sold 669,954 Supernus Pharmaceuticals shares in Q2 2015, an estimated $8.1M.
  • Kennedy Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Kennedy Capital Management's Supernus Pharmaceuticals position peaked at $8.1M in Q1 2015.
  • 165 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Kennedy Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.